Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516957 · ClinicalTrials.gov registry record · Phase 2
AMG 827 in Subjects With Psoriatic Arthritis
A Phase 2 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT01516957 is a Phase 2 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 168 participants.
The verdict
NCT01516957, a Phase 2 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
Interventions
- DRUG Placebo
- DRUG AMG 827 140
- DRUG AMG 827 280
- DRUG AMG 827 210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01516957
The ClinicalTrials.gov registry entry for NCT01516957 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01516957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01516957 about?
NCT01516957 is a clinical study titled "AMG 827 in Subjects With Psoriatic Arthritis". The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
What is the current status of trial NCT01516957?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2011-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01516957?
The interventions under investigation include: Placebo (DRUG), AMG 827 140 (DRUG), AMG 827 280 (DRUG), AMG 827 210 (DRUG).
Who is sponsoring clinical trial NCT01516957?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.